What is HC Wainwright’s Forecast for CMPX Q1 Earnings?

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Compass Therapeutics in a research report issued on Thursday, March 5th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.09) per share for the quarter. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS and Q4 2026 earnings at ($0.11) EPS.

CMPX has been the subject of a number of other research reports. Citizens Jmp set a $10.00 target price on Compass Therapeutics in a report on Wednesday, December 3rd. Leerink Partners raised shares of Compass Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 26th. Cantor Fitzgerald began coverage on shares of Compass Therapeutics in a report on Wednesday, December 3rd. They issued an “overweight” rating for the company. Citigroup initiated coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They set an “outperform” rating on the stock. Finally, Craig Hallum started coverage on shares of Compass Therapeutics in a research report on Friday, February 13th. They issued a “buy” rating and a $15.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $13.00.

Compass Therapeutics Price Performance

CMPX opened at $5.53 on Friday. The business has a fifty day simple moving average of $5.89 and a 200 day simple moving average of $4.78. Compass Therapeutics has a 1 year low of $1.33 and a 1 year high of $6.88. The company has a market capitalization of $983.57 million, a PE ratio of -12.29 and a beta of 1.48.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01.

Institutional Investors Weigh In On Compass Therapeutics

A number of large investors have recently modified their holdings of the business. Vivo Capital LLC boosted its stake in Compass Therapeutics by 70.0% in the second quarter. Vivo Capital LLC now owns 6,043,466 shares of the company’s stock valued at $15,713,000 after buying an additional 2,487,443 shares in the last quarter. Monashee Investment Management LLC raised its stake in Compass Therapeutics by 657.6% during the third quarter. Monashee Investment Management LLC now owns 1,250,000 shares of the company’s stock worth $4,375,000 after acquiring an additional 1,085,000 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Compass Therapeutics in the fourth quarter worth about $96,000. AXQ Capital LP bought a new position in shares of Compass Therapeutics in the fourth quarter worth about $222,000. Finally, ProShare Advisors LLC grew its holdings in shares of Compass Therapeutics by 41.0% during the 4th quarter. ProShare Advisors LLC now owns 23,972 shares of the company’s stock valued at $129,000 after purchasing an additional 6,968 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical?stage biotechnology company dedicated to the discovery and development of novel immuno?oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti?tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47?SIRP? pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.